🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,760 results for “Pharm” Clear

  1. Study of DFF332 alone and in combination with Everolimus or Immuno-oncology therapies in patients with renal cell carcinoma and other selected tumors.

    Novartis Pharmaceuticals

    Advanced, relapsed Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  2. Study of EGF816 in combination with selected targeted agents in EGFR-mutant NSCLC.

    Novartis Pharmaceuticals

    Patients with EGFR-mutant Non Small Cell Lung Cancer

    phase 1 other active

    1 trial

  3. Study of PIT565 in relapsed and/or refractory B-cell malignancies

    Novartis Pharmaceuticals

    Relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)

    phase 1 other active

    1 trial

  4. Study of REGN6569 and Cemiplimab in Adult Patients with Advanced Solid Tumor Malignancies

    Lacuna Pharma Pty Ltd

    Squamous Cell Carcinoma of Head and Neck

    phase 1 other active

    1 trial

  5. Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

    Novartis Pharmaceuticals

    Alzheimer’s Disease

    phase 1 other active

    1 trial

  6. Study of safety and efficacy of DKY709 alone or in combination with PDR001 in patients with advanced solid tumors.

    Novartis Pharmaceuticals

    Nasopharyngeal Carcinoma, Triple Negative Breast Cancer, Microsatellite Stable Colorectal Cancer, Non-Small Cell Lung Cancer, Cutaneous Melanoma

    phase 1 other active

    1 trial

  7. Study of safety and preliminary efficacy of VAY736 given alone or in combination with other antineoplastic agents in patients with NHL

    Novartis Pharmaceuticals

    Relapsed/refractory Non Hodgkin Lymphoma

    phase 1 other active

    1 trial

  8. Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Hepatic Impairment

    Taiho Pharma Netherlands B.V.

    Solid tumor, Acute myeloid lymphoma (AML), Myelodysplastic syndrome (MDS)

    phase 1 other active

    1 trial

  9. Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Renal Impairment

    Taiho Pharma Netherlands B.V.

    Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), or solid tumors

    phase 1 other active

    1 trial

  10. Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)

    IONIS PHARMACEUTICALS INC

    Multiple System Atrophy

    phase 1 other active

    1 trial

  11. Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

    Lacuna Pharma Pty Ltd

    B-cell non-Hodgkin lymphoma (NHL)

    phase 1 other active

    1 trial

  12. Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia

    Hutchmed Europe B.V.

    Primary immune thrombocytopenia (ITP)

    phase 1 other active

    1 trial

  13. Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR

    Novartis Pharmaceuticals

    Polymyalgia rheumatica (PMR), Giant cell arteritis (GCA)

    phase 1 other active

    1 trial

  14. Sublingual Tizanidine HCl

    Teva Pharma GmbH

    Traumatic Brain Injury

    phase 1 small molecule completed

    1 trial

  15. Sumatriptan succinate

    Teva Pharma GmbH

    Migraine Disorders

    phase 1 small molecule completed

    1 trial

  16. Sumatriptan succinate

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    3 trials

  17. TAK-114 10 mg capsule

    Takeda

    Clinical Pharmacology

    phase 1 small molecule completed

    1 trial

  18. TAK-233

    Takeda

    Clinical Pharmacology

    phase 1 small molecule completed

    1 trial

  19. TAK-573

    Teva Pharma GmbH

    Relapsed and/or Refractory Multiple Myeloma

    phase 1 small molecule terminated

    1 trial

  20. TAK-875 and Glimepiride

    Takeda

    Pharmacokinetics

    phase 1 small molecule completed

    1 trial

  21. TAK-935

    Takeda

    Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents

    phase 1 small molecule completed

    1 trial

  22. TD-0714

    Theravance Biopharma Ireland Umited

    Healthy

    phase 1 small molecule completed

    1 trial

  23. TD-0714

    Theravance Biopharma Ireland Umited

    Healthy Adults, Elderly Subjects

    phase 1 small molecule completed

    1 trial

  24. TD-1058

    Theravance Biopharma Ireland Umited

    Idiopathic Pulmonary Fibrosis (IPF)

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources